Home  »  Finance   »  Selling Your Akebia Therapeutics Inc. (AKBA) Stock...

Selling Your Akebia Therapeutics Inc. (AKBA) Stock? Here’s What You Need To Know

Akebia Therapeutics Inc. (NASDAQ:AKBA) price on Friday, March 17, fall -10.92% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $0.63.

A look at the stock’s price movement, the close in the last trading session was $0.71, moving within a range at $0.6348 and $0.7027. The beta value (5-Year monthly) was 0.90. Turning to its 52-week performance, $2.60 and $0.24 were the 52-week high and 52-week low respectively. Overall, AKBA moved -28.36% over the past month.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Akebia Therapeutics Inc.’s market cap currently stands at around $117.19 million, with investors looking forward to this quarter’s earnings report slated for May 08, 2023 – May 12, 2023. Analysts project the company’s earnings per share (EPS) to be -$0.14, which has seen fiscal year 2022 EPS growth forecast to increase to -$0.61 and about -$0.45 for fiscal year 2023. Per the data, EPS growth is expected to be 64.10% for 2023 and 26.20% for the next financial year.

Analysts have a consensus estimate of $48.35 million for the company’s revenue for the quarter, with a low and high estimate of $46.58 million and $50.12 million respectively. The average forecast suggests down to a -18.90% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue for 2022 to grow to $285.77 million, representing a 33.80% jump on that reported in the last financial year.

Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that AKBA is a 50% Buy. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.

AKBA’s current price about -22.86% and -20.16% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 38.96, while 7-day volatility ratio is 11.69% and 12.86% in the 30-day chart. Further, Akebia Therapeutics Inc. (AKBA) has a beta value of 0.77, and an average true range (ATR) of 0.11.

In the market, a comparison of Akebia Therapeutics Inc. (AKBA) and its peers suggest the former has performed considerably weaker. Data shows AKBA’s intraday price has changed -10.92% in last session and -72.87% over the past year. Comparatively, Johnson & Johnson (JNJ) has moved -1.07% on the day and only -12.69% in the past 12 months. Looking at another peer, we see that Novartis AG (NVS) price has dipped -0.71% on the day. However, the stock is -2.89% off its price a year ago. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are down -1.10% and -1.19% respectively in the last trading.

If we refocus on Akebia Therapeutics Inc. (NASDAQ:AKBA), historical trading data shows that trading volumes averaged 2.2 million over the past 10 days and 2.39 million over the past 3 months. The company’s latest data on shares outstanding shows there are 183.88 million shares.

The 0.20% of Akebia Therapeutics Inc.’s shares are in the hands of company insiders while institutional holders own 29.20% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 3.32 million on Jan 30, 2023, giving us a short ratio of 2.07. The data shows that as of Jan 30, 2023 short interest in Akebia Therapeutics Inc. (AKBA) stood at 1.81% of shares outstanding, with shares short falling to 4.66 million registered in Dec 29, 2022. Current price change has pushed the stock 10.02% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the AKBA stock continues to rise going into the next quarter.

Leave a Comment

Your email address will not be published. Required fields are marked *